These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1196872)

  • 41. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Long-term syndrome in the treatment of parkinsonism with L-dopa].
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1975; 21(1-4):108-25. PubMed ID: 1243997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical course of patients with idiopathic Parkinson's disease.
    Roos RA; Jongen JC; van der Velde EA
    Mov Disord; 1996 May; 11(3):236-42. PubMed ID: 8723138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
    Garcia-Borreguero D; Caminero AB; De La Llave Y; Larrosa O; Barrio S; Granizo JJ; Pareja JA
    Mov Disord; 2002 Sep; 17(5):934-41. PubMed ID: 12360542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The addition of bromocriptine to long-term dopa therapy in Parkinson's disease.
    Selby G
    Clin Exp Neurol; 1989; 26():129-39. PubMed ID: 2701877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 50. Primary progressive freezing gait.
    Achiron A; Ziv I; Goren M; Goldberg H; Zoldan Y; Sroka H; Melamed E
    Mov Disord; 1993 Jul; 8(3):293-7. PubMed ID: 8341293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapy of parkinsonism using L-Dopa (Brocadopa)].
    Jörg J
    Med Welt; 1975 Jan; 26(3):124-6. PubMed ID: 1110622
    [No Abstract]   [Full Text] [Related]  

  • 53. [A case of mental change resulting from L-dopa treatment].
    Gulmann NC
    Ugeskr Laeger; 1976 Oct; 138(41):2497-8. PubMed ID: 973254
    [No Abstract]   [Full Text] [Related]  

  • 54. [Comparison between EEG-finding and clinical picture in patients with Parkinsonism under L-dopa].
    Bengesser G
    Wien Med Wochenschr; 1975 Feb; 125(7-8):120-1. PubMed ID: 1146347
    [No Abstract]   [Full Text] [Related]  

  • 55. Studies on piribedil in Parkinsonism.
    Lieberman AN; Shopsin B; Brun YL; Boal D; Zolfaghari M
    Adv Neurol; 1975; 9():399-407. PubMed ID: 125032
    [No Abstract]   [Full Text] [Related]  

  • 56. Parkinsonism and levodopa: a five-year experience.
    Delaney P; Fermaglich J
    J Clin Pharmacol; 1976; 16(11-12):652-9. PubMed ID: 791974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of L-dopa on EEG tracings in patients with parkinsonism].
    Rudkowska A; Misztal S
    Pol Tyg Lek; 1975 Apr; 30(14):593-5. PubMed ID: 1129202
    [No Abstract]   [Full Text] [Related]  

  • 58. Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence.
    Hagenah J; Klein C; Sieberer M; Vieregge P
    J Neural Transm (Vienna); 1999; 106(3-4):301-7. PubMed ID: 10392538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?
    Indo T; Takahashi A
    Jpn J Med; 1986 May; 25(2):114-21. PubMed ID: 3747258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parkinsonism, levodopa, and intelligence.
    Loranger A; Sweet RD; Goodell H; McDowell F
    Int J Neurol; 1975; 10(1-4):276-81. PubMed ID: 1181314
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.